Stephen Sofen is an Advisor at 64x Bio.

‍

Stephen brings over 20 years of varied biotech CMC management and leadership experience from stints at Genzyme, Biogen, CRISPR Therapeutics, Kaleido Biosciences, and Abata Therapeutics. Stephen’s experience also includes numerous consulting and advising roles at venture firms and biotech startups as well as pro bono work at non-profit organizations focused on rare genetic diseases. He has been involved in projects that span numerous platform technologies including small molecules, oligonucleotides, monoclonal and polyclonal antibodies, recombinant proteins, autologous and allogeneic gene edited cell therapies, viral vectors, and polymeric drugs, from early stage through commercialization.

‍

Steve earned a BA in Chemistry at Reed College and a PhD in Inorganic Chemistry from the University of California, Berkeley. He also completed The Executive Program at the Darden School of Business of the University of Virginia.